U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07646535) titled 'A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism' on June 08.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.

Study Start Date: June 12

Study Type: INTERVENTIONAL

Condition: Primary Aldosteronism

Intervention: DRUG: SAL0140 Tablets

Drug: SAL0140 Tablets

DRUG: SAL0140 Tablets

SAL0140 Tablets

DRUG: SAL0140 placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shenzhen Salubris Pharmaceuticals Co.,...